Whitehawk Therapeutics presented data showing that PTK7 protein expression remains stable in EGFR wild-type non-small cell lung cancer (NSCLC) patients after standard treatments like chemotherapy and immunotherapy. This stability supports PTK7 as a reliable target for their next-generation antibody drug conjugate (ADC), HWK-007, currently in Phase 1 trials. The findings suggest HWK-007 could be effective in patients who have undergone multiple prior therapies, expanding treatment options for advanced lung cancer. Further clinical evaluation of HWK-007 is ongoing.
Johnson & Johnson announced that RYBREVANT combined with chemotherapy significantly improved overall survival in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. The Phase 3 PAPILLON study showed a...
South Korea's largest crypto exchange, Upbit, reported a weekly trading volume of 11.2 trillion won (about $8 billion), marking a 6.74% increase from the previous week. XRP emerged as the most actively traded asset, surpassing Bitcoin and USDT, espec...
The Kurv Technology Titans Select ETF (KQQQ) maintains a buy rating due to its selective, actively managed option strategy that offers strong income potential with an estimated 14.5% yield. Its active management allows dynamic positioning that has ou...
Injective Protocol has activated its IIP-677 mainnet upgrade, introducing Injective Mint, a platform for issuing SEC- and MiCA-compliant tokenized equities and bonds. The upgrade improves cross-chain interoperability, reduces block times, and optimiz...
Archax, a FCA-regulated digital securities exchange, has integrated with the Aptos blockchain to enable over 100 regulated tokenized securities and real-world assets onchain. The first asset is the MembersCap Tokenized Global Reinsurance Income Fund,...
